# Project 4: Multi-modality Metabolic Imaging for Monitoring Molecular Sub-types of Glioma

> **NIH NIH P01** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2020 · $511,629

## Abstract

The goal of this project is to develop tools for using 1H MR echo planar spectroscopic imaging (EPSI) and novel 
hyperpolarized 13C imaging to improve the management of in patients with glioma. We will tailor metabolic 
acquisitions for the specific molecular markers, such as 1p19q co-deletion, IDH mutation status and TERT 
promotor mutation (TERTp), which have been recently incorporated into the new WHO 2016 classification. In 
the previous cycle of this P01, we have identified several molecular markers to differentiate IDH mutation status 
and predict malignant progression based on ex vivo 1H HRMAS-NMR spectroscopy from image-guided tissue 
samples and in vivo 1H EPSI, and we have also developed, implemented and optimized acquisitions, post- 
processing and quantification of 1H EPSI and hyperpolarized [1-13C]pyruvate metabolic imaging for patients with 
glioma. In this proposed project, we will expand upon sequences used for 1H metabolic imaging and upon the 
agents used for hyperpolarized 13C imaging in order to determine which markers are the most relevant for 
evaluating patients from different molecular subgroups. 
In Aim 1 we will develop an integrated protocol that combines 1H lactate edited EPSI and [1-13C]pyruvate for 
patients with IDH-negative TERTp+ glioblastoma, and investigate the impact of treatment with RT and 
temozolomide on multiple metabolites, as well as their association with outcome. In Aim 2 we will evaluate 
metabolic changes during treatment with RT and temozolomide for patients with IDH+ astrocytoma in order to 
determine markers for early decision making by using 1H methods to detect 2-hydroxyglutarate (2HG) and 
hyperpolarized [2-13C]pyruvate metabolic imaging to detect differences in glutamate. In Aim 3 we will explore 
whether estimates of 2HG from 1H spectra or estimates obtained using hyperpolarized [1-13C]α-ketoglutarate 
metabolic imaging are more sensitive for identifying regions of malignant progression in recurrent tumor for 
patients with IDH+, 1p/19q co-deleted and TERTp+ oligodendroglioma. The results of the project will identify 
metabolic parameters that are indicative of early treatment effectiveness for patients from different molecular 
sub-groups and will enable rapid selection of the most appropriate therapies.

## Key facts

- **NIH application ID:** 10020344
- **Project number:** 5P01CA118816-12
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** Daniel B Vigneron
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $511,629
- **Award type:** 5
- **Project period:** 2007-07-01 → 2024-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10020344

## Citation

> US National Institutes of Health, RePORTER application 10020344, Project 4: Multi-modality Metabolic Imaging for Monitoring Molecular Sub-types of Glioma (5P01CA118816-12). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10020344. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*